Alexion Strikes Bold AI Partnership for Rare Disease Detection
AI partnership targets rare bone disease affecting 1 in 6,000 patients.
Partnership
A. Menarini Diagnostics and Nucleix Form Strategic Partnership for Non-Invasive Bladder Cancer Test in Europe
A. Menarini Diagnostics and Nucleix have announced a strategic commercial agreement to exclusively market the Bladder EpiCheck® test in Europe. This non-invasive, CE-marked urine test is designed to detect and monitor bladder cancer and upper tract urothelial carcinoma (UTUC), providing an alternative to invasive cystoscopy. The partnership was revealed at the 36th European Congress of … Read more